Core Viewpoint - Zhonghui Biotech-B (02627.HK) has announced a delay in its global offering schedule due to extreme weather conditions, with shares now expected to begin trading on August 11, 2025, instead of the previously planned August 8, 2025 [2]. Group 1: IPO Details - The company plans to issue 33.4426 million H-shares, representing 8.5% of the total shares post-issue, with an additional 15% over-allotment option [2][3]. - The expected share price range is between HKD 12.90 and HKD 15.50, aiming to raise approximately HKD 5.18 billion [2][3]. - The IPO will involve 90% international offering and 10% public offering, with no over-allotment option [2]. Group 2: Key Investors and Underwriters - The IPO has secured one cornerstone investor, Jiaxing Xinyang, which has committed to purchasing USD 13 million (approximately HKD 102 million) of the offering [2][3]. - The joint sponsors and global coordinators for the IPO are CITIC Securities and CMB International, with other underwriters including Livermore Securities, Futu Securities, and Bank of China International [2][3]. Group 3: Company Overview - Zhonghui Biotech, established in 2015, focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new methodologies [3]. - The company aims to replace traditional and imported vaccines in China with high-end vaccines and expand its competitive advantage internationally [3]. - Zhonghui Biotech currently has one commercialized product in China and two core products in development: a quadrivalent influenza virus subunit vaccine and a lyophilized human rabies vaccine [3].
中慧生物-B，因恶劣天气，IPO延至8月11日